Related Experiment Videos
Systemic chemotherapy for metastatic melanoma
1Division of Medical Oncology, Jefferson Medical College, Philadelphia.
Abstract:
The treatment of patients with metastatic melanoma remains a difficult problem. It is clear that more effective agents need to be developed. No single agent in conventional doses has been shown to be more effective than DTIC alone. The results obtained with detrorubicin in untreated patients are encouraging, but need further confirmation. If confirmed, combination regimens incorporating detrorubicin should be studied. Further experience is needed with high-dose cisplatin before it can be recommended for broader clinical use. Recent experience with the 4 drug combination of DTIC, BCNU, cisplatin, and tamoxifen is encouraging. The objective response rate is approximately 50% and patients with visceral disease have demonstrated regressions. CRs are not uncommon with occasional patients exhibiting durable remissions for as long as 3 years. An added benefit is that this regimen is well tolerated by most patients making it technically easy to administer. Finally, the role of interferon needs further study. The response rate to interferon alfa-2a is reasonably well defined at about 20%. Combinations of chemotherapeutic agents and interferons have only begun to be evaluated but the preliminary data are interesting.
Insights
Developing more effective treatments for metastatic melanoma is crucial. A four-drug combination including DTIC, BCNU, cisplatin, and tamoxifen shows promise with a 50% response rate and durable remissions.
Area of Science:
- Oncology
- Medical Oncology
- Dermatology
Background:
- Metastatic melanoma presents significant treatment challenges.
- Current single-agent therapies often lack superior efficacy compared to dacarbazine (DTIC).
- There is a critical need for novel and more effective therapeutic agents.
Purpose of the Study:
- To evaluate the efficacy and tolerability of novel treatment regimens for metastatic melanoma.
- To assess the potential of combination chemotherapy and interferon-based therapies.
Main Methods:
- Review of recent clinical experience with various chemotherapy agents and combinations.
- Analysis of objective response rates, including complete remissions (CRs) and durable remissions.
- Assessment of treatment tolerability and ease of administration.
Main Results:
- A four-drug combination (DTIC, BCNU, cisplatin, tamoxifen) demonstrated an objective response rate of approximately 50%.
- This regimen induced regressions in patients with visceral disease and occasional durable remissions up to 3 years.
- Interferon alfa-2a showed a response rate of about 20%, with preliminary data on combination therapies being interesting.
Conclusions:
- The four-drug combination regimen is a promising, well-tolerated, and easily administered option for metastatic melanoma.
- Further investigation into detorubicin-containing regimens and the role of interferons in combination therapy is warranted.
- High-dose cisplatin requires additional study before widespread clinical recommendation.